Skip to main content

Table 4 Performance characteristics of MLDA for IgG and IgM to PS, PI, CL, and β2GPI

From: Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay

  Sensitivity 95% CI Specificity 95% CI +LR 95% CI -LR 95% CI
anti-PS IgG 32.9 23.1 to 44.0 98.6 95.1 to 99.8 23.7 5.8 to 97.1 0.7 0.6 to 0.8
anti-PS IgM 20.0 12.1 to 30.1 99.3 96.2 to 100.0 28.8 3.9 to 212.6 0.8 0.7 to 0.9
anti-PI IgG 8.2 3.4 to 16.2 100.0 97.5 to 100.0   0.9 0.9 to 1.0
anti-PI IgM 3.5 0.7 to 10.0 100.0 97.5 to 100.0   1.0 0.9 to 1.0
anti-CL IgG 45.9 35.0 to 57.0 97.2 93.0 to 99.3 16.5 6.1 to 44.6 0.6 0.5 to 0.7
anti-CL IgM 38.8 28.4 to 50.0 93.8 88.5 to 97.1 6.2 3.1 to 12.3 0.6 0.6 to 0.8
anti-β2 GPI IgG 36.5 26.7 to 47.6 100.0 97.5 to 100.0   0.6 0.5 to 0.8
anti-β2 GPI IgM 31.8 22.1 to 42.8 94.4 89.4 to 97.6 5.7 2.7 to 12.1 0.7 0.6 to 0.8
  1. Investigating 85 APS patients, 65 DC patients, and 79 NHS, sensitivity, specificity, and likelihood ratios were calculated.
  2. anti-β2 GPI, anti-beta2-glycoprotein I; anti-CL, anti-cardiolipin; +LR, positive likelihood ratio; -LR, negative likelihood ratio.